Optimising Metered Dose Inhalers for Respiratory Disorders
Respiratory disorders affect hundreds of millions of people worldwide, with an estimated 300 million people suffering from asthma and a further 210 million with chronic obstructive pulmonary disease (COPD).
The primary treatment of these diseases is through inhaled medication, and metered dose inhalers (MDIs) are the most widely used delivery system.
MDIs have a number of advantages over alternative systems such as nebulsers or oral therapy for respiratory diseases.
Download to find out more.